Evidence map›Paper›PMID 31453961›Full record

Trial reportMenopause (New York, N.Y.)2019

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.

Irwin Goldstein, James A Simon, Andrew M Kaunitz, Corrado Altomare, Yuki Yoshida, Julie Zhu, Sam Schaffer, Graziella Soulban

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Menopause (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Fractional COMedicina (Kaunas, Lithuania) · 2023
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Irwin GoldsteinDirector, Sexual Medicine, Alvarado Hospital, San Diego, CA.
James A SimonGeorge Washington University, School of Medicine, IntimMedicine Specialists, Washington, DC.
Andrew M KaunitzUniversity of Florida, College of Medicine-Jacksonville, Jacksonville, FL.
Corrado AltomareShionogi Inc, Florham Park, NJ.
Yuki YoshidaShionogi Inc, Florham Park, NJ.
Julie ZhuShionogi Inc, Florham Park, NJ.
Sam SchafferDuchesnay Inc, Quebec, Canada.
Graziella SoulbanDuchesnay Inc, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo prospectively evaluate the effects of ospemifene on the vulva and vagina in postmenopausal women using vulvar-vestibular photography and direct visual assessments.

methodsPostmenopausal women (aged 40-80 years) with moderate to severe vaginal dryness as their most bothersome symptom (MBS) were randomized to daily ospemifene 60 mg or placebo in this 12-week, multicenter, double-blind, phase 3 study. Vulvar-vestibular photographic images were captured at baseline and week 12 and were independently assessed with the Vulvar Imaging Assessment Scale (VIAS). Changes from baseline in Vaginal and Vulvar Health Indices (VHI and VuHI) with ospemifene versus placebo were analyzed at weeks 4, 8, and 12. Correlations between VIAS, VHI, and VuHI, with vaginal dryness severity and the Female Sexual Function Index (FSFI) scores were also assessed.

resultsIn all, 631 eligible participants were randomized (ospemifene 316, placebo 315) and included in the intention-to-treat population. Compared with placebo, ospemifene significantly improved total scores for VIAS (P = 0.0154), VHI (P < 0.0001), and VuHI (P < 0.0001) from baseline to week 12; significant VHI (P < 0.0001) and VuHI (P = 0.002) improvements were observed at week 4. Most VHI and VuHI individual items were significantly better with ospemifene versus placebo at week 12 (P < 0.05). Most correlations between the vulvovaginal assessment total scores versus vaginal dryness severity and FSFI scores were significant (P < 0.05).

conclusionImprovements observed in vulvovaginal health with ospemifene assessed by prospective vulvar-vestibular photography and other direct visual assessments support its efficacy in addition to the treatment of moderate to severe vaginal dryness due to menopause and the use of photographic and direct visual evaluations in future clinical trials. VIDEO SUMMARY: Supplemental Digital Content 1, http://links.lww.com/MENO/A415.

Indexed as

Administration, OralAdultAgedAged, 80 and overAtrophyCross-Sectional StudiesDouble-Blind MethodFemaleHumansMiddle AgedPhotographyProspective StudiesSelective Estrogen Receptor ModulatorsTamoxifenTreatment OutcomeUnited StatesOspemifeneSelective Estrogen Receptor ModulatorsTamoxifen

Identifiers

PMID31453961
PMCPMC6738630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.